Gliosarcoma Global Market Report 2025

Gliosarcoma is a rare and aggressive brain tumor composed of both glial and sarcomatous tissue, primarily occurring in the cerebral hemisphere. It is studied to understand tumor biology and develop treatment strategies for glioblastoma and other brain malignancies.

The primary diagnostic methods for gliosarcoma include imaging techniques, histopathological examination, and biomarker testing. Imaging techniques, such as MRI, CT, and PET scans, are non-invasive methods used to visualize internal structures and detect abnormalities. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with end users including hospitals, cancer research institutes, and specialty clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The gliosarcoma market research report is one of a series of new reports from The Business Research Company that provides gliosarcoma market statistics, including gliosarcoma industry global market size, regional shares, competitors with a gliosarcoma market share, detailed gliosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the gliosarcoma industry. This gliosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gliosarcoma market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to an increase in healthcare expenditure, a rising number of clinical trials, an increase in the global aging population, a growing prevalence of comorbidities like diabetes and hypertension, and an increase in healthcare insurance coverage.

The gliosarcoma market size is expected to see strong growth in the next few years. It will grow to $1.53 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing incidence of gliosarcoma, rising awareness about brain cancers, growth in research funding for brain cancer, rising demand for personalized treatments, and expansion of healthcare infrastructure. Major trends in the forecast period include advances in diagnostic techniques, development of targeted therapies, availability of advanced imaging technologies, advancements in surgical techniques, and technological innovations in drug delivery systems.

The forecast of 5.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. rare cancer treatment by increasing costs for ifosfamide and radiation therapy components imported from China and Belgium, potentially compromising survival rates and increasing neuro-oncology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of brain tumors is expected to drive growth in the gliosarcoma market. A brain tumor is an abnormal growth of cells in the brain, which can be either benign or malignant and may cause symptoms such as headaches, seizures, and vision problems. The increasing number of brain tumor cases is attributed to improved diagnostic technologies, heightened awareness, and environmental and lifestyle factors that may contribute to greater exposure to risk factors. Gliosarcoma treatment plays a crucial role in managing this aggressive and rare cancer, aiming to alleviate symptoms, extend survival, and enhance the patient's quality of life. For example, in October 2022, the National Library of Medicine, a US-based biomedical library operated by the United States federal government, reported that in 2023, the United States recorded 94,390 new cases of brain and central nervous system (CNS) tumors, up from 93,470 cases in 2022. Malignant cases increased from 26,670 to 26,940, while non-malignant cases rose from 66,800 to 67,440. The growing incidence of brain tumors is thus fueling demand for gliosarcoma treatment.

Leading companies in the gliosarcoma market are focusing on developing advanced wearable technology to enhance cancer treatment and monitoring. Wearable devices are electronic gadgets worn on the body that track and analyze health data, offering real-time insights and improving patient engagement. For instance, in November 2024, Novocure Ltd., a UK-based oncology company, received U.S. Food and Drug Administration (FDA) approval for the use of Head Flexible Electrode (HFE) transducer arrays alongside Optune Gio for treating adult patients with glioblastoma multiforme (GBM). Optune Gio is a portable, wearable device that uses non-invasive arrays to deliver tumor-treating fields (TTFields), which apply physical forces to electrically charged components of dividing cancer cells, disrupting their rapid growth. The newly introduced HFE arrays are 50% thinner and one-third lighter than the ceramic discs used in the existing Optune Gio arrays, as they are made from a flexible polymer material, enhancing patient comfort and usability.

In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences in a $1.3 billion deal. This acquisition strengthens Merck's oncology portfolio by advancing innovative therapies for glioblastoma and other cancers, further expanding its expertise in cancer treatment. Modifi Biosciences, based in the U.S., specializes in developing treatments for glioblastoma, reinforcing Merck's commitment to addressing complex oncological challenges.

Major players in the gliosarcoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma, Bio-Rad Laboratories Inc., Carl Zeiss AG, Elekta AB, Novocure Ltd., ImmunityBio Inc., Immatics Biotechnologies, Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., Komipharm International Co. Ltd., Kintara Therapeutics Inc., Aveta Biomics Inc., Vigeo Therapeutics Inc.

North America was the largest region in the gliosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gliosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gliosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gliosarcoma market consists of revenues earned by entities by providing services such as molecular diagnostics, clinical trials and research, palliative care services, rehabilitation, and recovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gliosarcoma market also includes sales of diagnostic kits, research reagents, and patient monitoring devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gliosarcoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gliosarcoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gliosarcoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gliosarcoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diagnosis Method: Imaging Techniques; Histopathological Examination; Biomarker Testing
• 2) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy
• 3) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics
• Subsegments:
• 1) By Imaging Techniques: Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan; Positron Emission Tomography (PET) Scan
• 2) By Histopathological Examination: Hematoxylin and Eosin (H&E) Staining; Immunohistochemistry (IHC); Electron Microscopy
• 3) By Biomarker Testing: IDH Mutation Testing; MGMT Promoter Methylation Testing; ATRX Mutation Testing; TP53 Mutation Analysis
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Bristol-Myers Squibb Company; Novartis AG; Eli Lilly and Company; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Sumitomo Dainippon Pharma; Bio-Rad Laboratories Inc.; Carl Zeiss AG; Elekta AB; Novocure Ltd.; ImmunityBio Inc.; Immatics Biotechnologies; Karyopharm Therapeutics Inc.; Celon Laboratories Pvt. Ltd.; Komipharm International Co. Ltd.; Kintara Therapeutics Inc.; Aveta Biomics Inc.; Vigeo Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.